Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen

study id #: NCT04644393

condition: Spinal Muscular Atrophy

status: Not yet recruiting

The Motor Function Measure (MFM), a reliable tool assessing motor function and its progression in most neuromuscular diseases, is widely used in France in many teams. It can be used regardless of the severity of the motor impairment or the ambulatory status of the patient, allowing its use throughout the whole follow-up period of the patient, even in case of the loss of walking. Two versions of the MFM exist, one composed of 32 items validated for patients from 6 years old (MFM-32) and a shorter version composed of 20 items validated for patients between 2 and 6 years old (MFM-20).

In order to show the possible use of MFM-20 as early as the age of 2 years to validly and reliably monitor the evolution of the motor function of children treated with Nusinersen, we propose in this project to study the sensitivity to treatment-induced change of MFM-20 and the validity of the scale in this population.

results: https://clinicaltrials.gov/ct2/show/results/NCT04644393

last updated: February 04, 2022

start date: November 2020

estimated completion: March 2021

last updated: November 25, 2020

size / enrollment: 40

primary outcomes:

• MFM-20 responsiveness
  The MFM-20 sensitivity to change indexes considered will be the effect amplitude and the Standardized Response Mean (SRM).
• At least 6 Months after the first MFM-20 assessment, and at maximum 24 months
  

inclusion criteria:

exclusion criteria: Criteria:

- Patients with associated cognitive impairment making impossible evaluation of motor function
Patients participating to a clinical study with a potential effect on their motor function.

sponsor: Hospices Civils de Lyon

contacts: Laure LE GOFF, MD, +33 4 72 12 95 04, [email protected]

trial center locations: France

• Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
  Laure LE GOFF, MD, +33 4 72 12 95 04, [email protected]
  
  
• Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
  Andreea SEFERIAN, MD, 01 44 73 65 37, [email protected]
  
  
• Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
  Susana QUIJANO-ROY, MD, 01.47.41.78.90;, [email protected]
  
  
• Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
  Capucine De LATTRE, MD, 02 40 34 76 74, [email protected]
  
  
• Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
  Julien DURIGNEUX, MD, 02 41 35 44 45, [email protected]
  
  
• Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
  Gaelle Gousse, MD, 04 77 82 87 29, [email protected]
  
  
• Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
  Catherine SARRET, MD, 04.73.75.06.53;, [email protected]
  
  
• Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
  Claude CANCES, MD, 05.34.55.85.77;, [email protected]